button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

mHNSCC - L2 - PDL1 negative metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 negative

versus durvalumab alone
durvalumab plus tremelimumab vs. durvalumab alone 1 certainty unassessable-1% certainty unassessable+13%-
versus tremelimumab
durvalumab plus tremelimumab vs. tremelimumab 1 certainty unassessable-26% certainty unassessable-25%-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons